Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1370 participants.
Also called NCT02160145
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,370 participants
- Registry
-
NCT02160145
-
- Other papers using this trial's data
- Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Norway, Poland, Puerto Rico, Romania, Russia, South Africa, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02160145. Randomized; quadruple masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2017-04-18 (actual). Results posted on 2018-08-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
- Condition
- Chronic Kidney Disease
- Condition
- Autosomal Dominant Polycystic Kidney Disease
- Intervention (Drug)
- Tolvaptan (OPC-41061)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Record details
- Record id
cardio:ct-nct02160145- Content hash
0ce2e540e9585a4ddc6ebb304940e3b16fea91a0381b1f275ee4aeaa1ba51980